Bad Blood: Secrets and Lies in a Silicon Valley Startup

Bad Blood: Secrets and Lies in a Silicon Valley Startup Audible Audiobook – Unabridged

4.7 out of 5 stars 13,956 ratings

Amazon Price
New from Used from
Kindle
Audible Audiobook, Unabridged
$0.00
Free with your Audible trial

Read & Listen

Switch between reading the Kindle book & listening to the Audible narration with Whispersync for Voice.
Get the Audible audiobook for the reduced price of $2.99 after you buy the Kindle book.
  • Get this audiobook free then 1 credit each month, good for any title you like - yours to keep, even if you cancel
  • Listen all you want to the Plus Catalogue—a selection of thousands of Audible Originals, audiobooks and podcasts, including exclusive series
  • Exclusive member-only deals
  • $16.45 a month after 30 days. Cancel anytime
By completing your purchase, you agree to Audible’s Conditions Of Use and Privacy Notice.
Sold and delivered by Audible, an Amazon company

Product details

Listening Length 11 hours and 36 minutes
Author John Carreyrou
Narrator Will Damron
Whispersync for Voice Ready
Audible.com.au Release Date 31 May 2018
Publisher Macmillan Digital Audio
Program Type Audiobook
Version Unabridged
Language English
ASIN B07CXY65VV
Best Sellers Rank 726 in Audible Books & Originals (See Top 100 in Audible Books & Originals)
1 in Pharmaceutical & Biotechnology Industry
2 in Biotechnology (Books)
3 in White Collar Crime Accounts

Customer reviews

4.7 out of 5 stars
4.7 out of 5
13,956 global ratings

Review this product

Share your thoughts with other customers

Read reviews that mention

Top reviews from Australia

Reviewed in Australia on 5 November 2018
Verified Purchase
2 people found this helpful
Report abuse
Reviewed in Australia on 18 April 2022
Verified Purchase
Reviewed in Australia on 12 August 2018
Verified Purchase
3 people found this helpful
Report abuse
Reviewed in Australia on 24 July 2019
Verified Purchase
Reviewed in Australia on 25 March 2019
Verified Purchase
2 people found this helpful
Report abuse

Top reviews from other countries

Natalia Rice
5.0 out of 5 stars The best read of the season; the author deserves an award.
Reviewed in the United Kingdom on 2 July 2018
Verified Purchase
112 people found this helpful
Report abuse
David
5.0 out of 5 stars If something sounds too good to be true it probably is.
Reviewed in the United Kingdom on 3 April 2019
Verified Purchase
23 people found this helpful
Report abuse
CJP
5.0 out of 5 stars One of the best written books I have read
Reviewed in the United Kingdom on 27 July 2018
Verified Purchase
24 people found this helpful
Report abuse
Denise L
5.0 out of 5 stars The author deserves a gazillion awards
Reviewed in the United Kingdom on 8 August 2018
Verified Purchase
20 people found this helpful
Report abuse
Djilly L.
5.0 out of 5 stars Page turner
Reviewed in the United Kingdom on 24 June 2019
Verified Purchase
Customer image
5.0 out of 5 stars Page turner
Reviewed in the United Kingdom on 24 June 2019
The core of this tragic story is quite straight forward, and has sadly been witnessed in many variants in financial markets over time. Yet there is such an ridiculousness about some events in this story that you wouldn’t be able to make it up as fiction.

If you weren’t aware you’ll see how Silicon Valley provides the perfect breeding ground for a combination of hubris, absence of ethics and a gold-rush-blindness. It’s about a start-up company and its rock–star founder/CEO that has developed supposedly easier and faster blood tests, potentially revolutionizing the medical world. Well-known, high-profile investors lined up to back the company and helped to secure a market cap of $9 bln at its IPO. . If you are not familiar with the actual events, I will try not to spoil the story. But there was an issue with the entire proposition, a big one.. And it’s fascinating how the CEO, with her Steve Jobs-Syndrome, manged to pull rational and experienced people into her cult.

So ultimately it’s another disturbing case about how regulators, investors, staff and sadly patients were all misled through bogus claims and plain fraud with quality standards. The latter part of the book deals with the subsequent threats, lawsuits after the author, a Wall Street Journal journalist that obviously portrays himself in clever light, exposed all this.

As a professional investor it’s the type of book that will entertain you on a not-too lengthy flight. But it also serves as a reminder not to close your eyes to the pitfalls and red flags when investing in companies. A lack of oversight and serious governance issues lie at the heart of this drama; the well-respected board of the company included no-one with experience the medical field to properly assess what the company was actually trying to achieve..
Images in this review
Customer image Customer image Customer image
Customer imageCustomer imageCustomer image
6 people found this helpful
Report abuse